Medtronic

Global Ventilators Market Focused Insights and Outlook 2024-2029 - KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic & GE Healthcare Lead the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, March 18, 2024
Managed Care, General Health, Oncology, Medical Devices, Infectious Diseases, Hospitals, Health Technology, Surgery, Biotechnology, Nursing, Medical Supplies, Practice Management, Health, Growth, Prevalence, Application, Molecular Modeling Database, Incidence, Patient, Ventilation, Hospital, Acute respiratory distress syndrome, GE HealthCare, Asthma, Medtronic, COPD, Nursing care plan, ICU, USD, Ageing, Medical device

The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.

Key Points: 
  • The global ventilators market, valued at USD 1.75 billion in 2023, is expected to grow at a CAGR of 6.50% from 2023 to 2029.
  • The global ventilators market is one of the fastest-growing segments in the medical devices market.
  • The changing healthcare services in emerging markets and significant achieved development with developed countries consistently drive the ventilator market growth.
  • KoninKlijke Philips, Hamilton Medical, Resmed, Medtronic plc, & GE Healthcare are some leading players currently dominating the global ventilators market.

QuantalX Secures Spot in FDA's Prestigious Total Life Cycle Advisory Program (TAP)

Retrieved on: 
Thursday, April 4, 2024
Diagnosis, NPH, Movement disorder, Growth, Cerebrospinal fluid, CSF, Risk, Patient, DSM-IV codes, Stroke, TAP, Doctor of Philosophy, Medtronic, Science, Approximation error, Normal pressure hydrocephalus, Food, FDA, VPS, Dementia, Pharmaceutical industry

NEW YORK, April 4, 2024 /PRNewswire/ -- QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders using the Delphi-MD medical device, announced today its selection to participate in the highly prestigious Total Life Cycle Advisory Program (TAP) initiated by the U.S. Food and Drug Administration (FDA). The program will focus on advancing Delphi-MD's unique Direct Electrophysiology Imaging technology, enabling the early detection of Normal Pressure Hydrocephalus (NPH) disease, with high accuracy rates, and the prediction of patients' response to ventriculoperitoneal shunting (VPS). The TAP program brings together the FDA, major health insurers, healthcare organizations, and industry leaders in a collaborative effort to construct a comprehensive strategy for technologies that can benefit the general population. This strategic framework spans crucial elements, such as value creation in the U.S. market, meticulous preparation for regulatory approval, meaningful engagement with insurers, and the establishment of a robust market presence with customers.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders using the Delphi-MD medical device, announced today its selection to participate in the highly prestigious Total Life Cycle Advisory Program (TAP) initiated by the U.S. Food and Drug Administration (FDA).
  • "The acceptance into the Total Life Cycle Advisory Program is a truly prestigious and significant opportunity for QuantalX," remarked Iftach Dolev.
  • The Total Life Cycle Advisory Program aims to guide innovative technologies through the entire product life cycle, ensuring regulatory compliance, market adoption, and enhanced positive patient impact.
  • The valuable experience and insights within this program are expected to accelerate QuantalX's market entry and establish a solid foundation for future growth.

DDL Expands its Offerings with Addition of Consulting Services Focused on Packaging Process Development

Retrieved on: 
Tuesday, April 2, 2024
Automation, B.M.S. College of Engineering, Harvard Business School, Graduate certificate, EDEN, DDL, Medtronic, Engineering, DePuy Synthes, EMBA, ISO, RIT, Printing, Consultant

EDEN PRAIRIE, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- DDL, a third-party testing laboratory, is thrilled to announce the expansion of its service portfolio with the introduction of consulting services tailored to packaging process development. Additionally, DDL is pleased to welcome Abhi Gautam as Executive Engineer to its team to spearhead this innovative consulting initiative.

Key Points: 
  • EDEN PRAIRIE, Minn., April 2, 2024 /PRNewswire-PRWeb/ -- DDL, a third-party testing laboratory, is thrilled to announce the expansion of its service portfolio with the introduction of consulting services tailored to packaging process development.
  • Additionally, DDL is pleased to welcome Abhi Gautam as Executive Engineer to its team to spearhead this innovative consulting initiative.
  • DDL's consulting services are designed to equip clients with the insights and guidance needed to optimize their packaging processes, mitigate risks, and enhance overall product performance.
  • For further information regarding DDL's consulting services, comprehensive testing offerings, or to request a quote, please visit http://www.DDLtesting.com or contact us directly at 800-229-4235.

DDL Expands its Offerings with Addition of Consulting Services Focused on Packaging Process Development

Retrieved on: 
Wednesday, March 27, 2024
Automation, B.M.S. College of Engineering, Harvard Business School, Graduate certificate, EDEN, DDL, Medtronic, Engineering, DePuy Synthes, EMBA, ISO, RIT, Printing, Consultant

EDEN PRAIRIE, Minn., March 27, 2024 /PRNewswire-PRWeb/ -- DDL, a third-party testing laboratory, is thrilled to announce the expansion of its service portfolio with the introduction of consulting services tailored to packaging process development. Additionally, DDL is pleased to welcome Abhi Gautam as Executive Engineer to its team to spearhead this innovative consulting initiative.

Key Points: 
  • EDEN PRAIRIE, Minn., March 27, 2024 /PRNewswire-PRWeb/ -- DDL, a third-party testing laboratory, is thrilled to announce the expansion of its service portfolio with the introduction of consulting services tailored to packaging process development.
  • Additionally, DDL is pleased to welcome Abhi Gautam as Executive Engineer to its team to spearhead this innovative consulting initiative.
  • DDL's consulting services are designed to equip clients with the insights and guidance needed to optimize their packaging processes, mitigate risks, and enhance overall product performance.
  • For further information regarding DDL's consulting services, comprehensive testing offerings, or to request a quote, please visit http://www.DDLtesting.com or contact us directly at 800-229-4235.

Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

Retrieved on: 
Wednesday, March 27, 2024
Hemodynamics, Aortic stenosis, Patient, Medtronic, Quality of life, Heart failure, Coronary, TAVR, FX, FDA, Physician

DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

Key Points: 
  • DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.
  • The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.
  • The Evolut FX+ TAVR system offers larger coronary access windows through a modified diamond-shaped frame design, which is four times larger than previous iterations of the Evolut TAVR system.
  • If left untreated, 50% of patients with symptomatic severe aortic stenosis can die from heart failure in as little as two years.2
    The Evolut FX+ TAVR system is indicated for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate, and low) in the U.S.

Music, Advanced Medicine, and Robotics Merge in Groundbreaking UltraCon 2024 Ultrasound Presentations

Retrieved on: 
Tuesday, March 26, 2024
Malta at War Museum, Amputation, FACP, AIUM, Permeability, Medtronic, MD, Robotics, American Institute, Creativity, Music, Liquid biopsy, Machine learning, Health, Rehabilitation, Medical device

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- The upcoming UltraCon 2024 conference, organized by the American Institute of Ultrasound in Medicine (AIUM), is set to spotlight groundbreaking advancements in medical technology with keynotes from industry luminaries Dr. Omar Ishrak and Dr. Gil Weinberg. This premier event, taking place from April 6–10 in Austin, Texas, will draw professionals from across the medical imaging spectrum to discuss the future of ultrasound technology and its applications.

Key Points: 
  • "Their groundbreaking work exemplifies the spirit of innovation that drives our field forward, offering new ways to enhance patient care and improve lives."
  • "The future of ultrasound technology lies at the intersection of innovation and patient care," stated Dr. Ishrak.
  • "Ultrasound will play a significant role in shaping the future of healthcare, and at UltraCon 2024, I look forward to exploring how advancements in imaging can redefine what's possible in diagnostics and treatment."
  • For a list of all UltraCon 2024 exhibitors, please visit this link .

Innovation in Healthcare and Digital Technologies Boosts European Patent Applications by U.S. Companies

Retrieved on: 
Tuesday, March 19, 2024
Boston Scientific, Growth, Biotechnology, Unitary, Unitary patent, Environment, EPO, Medtronic, Unified Patent Court, Samsung, Johnson & Johnson, European Patent Convention, Invention, Patent, Ericsson, South Korea, Multimedia, SME

MUNICH, March 19, 2024 /PRNewswire/ -- U.S. companies filed 48 155 patent applications at the European Patent Office last year, an increase of 0.4% compared to 2022, according to the EPO's Patent Index 2023 .

Key Points: 
  • MUNICH, March 19, 2024 /PRNewswire/ -- U.S. companies filed 48 155 patent applications at the European Patent Office last year, an increase of 0.4% compared to 2022, according to the EPO's Patent Index 2023 .
  • The U.S. thus accounted for 24.2% of the total patent applications received by the EPO in 2023.
  • The U.S. consistently ranks as the top filing country at the EPO, and the number of patent applications has increased by +31.3% since 2014.
  • The U.S. growth was driven by increased patent applications in healthcare and digital technologies, making up the five leading U.S technology fields with the most patent applications in Europe: medical technology (6 098 patent applications), computer technology (5 111), digital communication (5 008), pharmaceuticals (3 802), biotechnology (2 751).

Methodist Le Bonheur Healthcare first in Tennessee to offer "paradigm-shifting" technology for AFib patients

Retrieved on: 
Thursday, March 14, 2024
MLH, Le Bonheur Children's Hospital, Heat, Atrial fibrillation, Anesthesia, Patient, Methodist University Hospital, PFA, Medtronic, Freezing, Arrhythmia, Ventricular fibrillation, Methodism, Cardiac electrophysiology, Hospital

MEMPHIS, Tenn. , March 14, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare is proud to announce it is the first healthcare system in Tennessee to offer the Medtronic PulseSelect™ Pulsed Field Ablation (PFA) technology to patients suffering from atrial fibrillation (AF).

Key Points: 
  • MEMPHIS, Tenn. , March 14, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare is proud to announce it is the first healthcare system in Tennessee to offer the Medtronic PulseSelect™ Pulsed Field Ablation (PFA) technology to patients suffering from atrial fibrillation (AF).
  • "Pulsed Field Ablation is a paradigm-shifting technology," said Dr. Yehoshua Levine, division chief of cardiac electrophysiology at Methodist Le Bonheur Healthcare who performed the first PFA at Methodist University Hospital.
  • "PFA allows us to deliver timely treatment to more patients when they need help the most," said Dr. James Litzow, cardiac electrophysiologist with Methodist Le Bonheur Germantown Hospital.
  • Across the MLH system , the cardiovascular team at Methodist University Hospital conducted the first PFA for the healthcare system on March 11 with Methodist Le Bonheur Germantown Hospital's cardiovascular team conducting its first PFA on March 12.

Rice Biotech Launch Pad adds William McKeon to external advisory board

Retrieved on: 
Thursday, March 14, 2024
Harris Health System, Research, Launch pad, Growth, Bill, Goldman Sachs, Rice University, Trustee, Integration, Patient, Stanford University Medical Center, Neuroscience, University, Faculty, Medtronic, MicroPort, CTMC, Roger Williams University, Texas Medical Center, Argonne National Laboratory, Rice, Jefferies, Greater Houston Partnership, College of Engineering (KNUST), MD Anderson Cancer Center, McKeon, Pharmaceutical industry

HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.

Key Points: 
  • HOUSTON, March 14, 2024 /PRNewswire/ -- Rice University today announced the addition of William McKeon to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "The appointment of a figure like Bill McKeon, who heads the largest medical city in the world at TMC, to the Launch Pad's external advisory board marks another highpoint of our commitment to the city of Houston," said Paul Wotton , executive director and chairman of the Rice Biotech Launch Pad.
  • "We are delighted to welcome Bill McKeon to the Launch Pad's remarkable external advisory board as he is a truly skilled leader whose local influence and strategic guidance will help elevate the Rice Biotech Launch Pad as a source for clinical advancements," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the accelerator.
  • "I am honored to join the exceptional advisory board of the Rice Biotech Launch Pad," said McKeon.

Extracorporeal Membrane Oxygenation Machine Market Projected to Reach $1,085.63 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Wednesday, March 13, 2024
Temperature, Component, Growth, LivaNova, Extracorporeal membrane oxygenation, Getinge Group, Intelligence, Fresenius Medical Care, Incidence, COVID-19, Patient, Pulmonary hypertension, Research, Cannula, Meconium aspiration syndrome, Carbon, ECMO, Heart, Arteriovenous, Periodic breathing, Workforce, Blood, Hemolysis, Medtronic, Nursing care plan, PPHN, Table, Ageing, Medical device

The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.

Key Points: 
  • The extracorporeal membrane oxygenation (ECMO) machine, a crucial medical device, offers extended cardiac and respiratory support to patients with insufficient gas exchange capabilities, marking a significant advancement in critical care.
  • Furthermore, market prospects include integrating ECMO with other extracorporeal treatments and concentrated research efforts to expand usage indications.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Extracorporeal Membrane Oxygenation Machine Market.
  • "Dive into the Extracorporeal Membrane Oxygenation Machine Market Landscape: Explore 196 Pages of Insights, 474 Tables, and 26 Figures"